The Wyss Institute for Biologically Inspired Engineering at Harvard University said that it was awarded a USD 9.25 million contract from the Defence Advanced Research Projects Agency (DARPA) to further advance its blood-cleansing technology and help accelerate its translation to humans as a new type of sepsis therapy.
The "Spleen-on-a-chip" device will be used to treat bloodstream infections that are the leading cause of death in critically ill patients, researchers said.
To rapidly cleanse the blood of pathogens, the patient's blood is mixed with magnetic nanobeads coated with a genetically engineered version of a human blood 'opsonin' protein that binds to a wide variety of bacteria, fungi, viruses, parasites, and toxins.
"In just a few years we have been able to develop a suite of new technologies, and to integrate them to create a powerful new device that could potentially transform the way we treat sepsis," said Wyss founding director and project leader, Don Ingber.
More From This Section
"The continued support from DARPA enables us to advance our device manufacturing capabilities and to obtain validation in large animal models, which is precisely what is required to enable this technology to be moved towards testing in humans," Ingber said in a statement.
SLIPS is a super-hydrophobic coating inspired from the slippery surface of a pitcher plant that repels nearly any material it contacts, researchers said.
By coating the inner surface of the channels of the device with SLIPS, blood cleansing can be carried out without the need for anticoagulants to prevent blood clotting.